

Curriculum Vitae
Howard Mandell, B.A., M.D., FRCPS

1987 Electromyography Fellowship EMG: Director: Dr. J. Kelly, Jr. M.D.
Muscle, Nerve Biopsy and Pathological Interpretation
Dr. L. Adelman, M.D., Dr. T. Munsat, M.D.
Tufts-New England Medical Center

Medical Licensure:

1981 LMCC (Canada)
1990 Board Certified in Neurology (USA)
1990 Specialist Certification in Neurology (Canada)
1990 Fellow Royal College (FRCP (C))
1993 Certification in EMG ABEM April

Professional Organization Memberships:

Canadian Medical Association
American Medical Association
American Academy of Neurology
South Carolina Medical Association
York County Medical Society

Publications:

Antibodies to Lyme Disease are Normal in Patients with Amyotrophic Lateral Sclerosis

Mandell H., Steere A., Reinhardt B., Munsat T.

New England Journal of Medicine, 1989

Antibodies to Borrelia burgdorferi in Amyotrophic Lateral Sclerosis

Mandell H., Munsat T.

Abstract presented at the American Neurological Association Scientific Meeting, October 1988

Cardiorespiratory Reflexes in Diabetes Mellitus

Kennedy W.R., Navarro X., Sakata M., **Mandell H.**, Knox , C.

Diabetes Care, Physiological and Clinical Correlates, 1989

Cardiorespiratory Reflexes in Diabetes Mellitus

Kennedy W.R., Navarro X., **Mandell H.**

Abstract presented at the American Academy of neurology Scientific Meeting, April 1988

Neuromuscular Manifestation of Wegener's Granulomatosis: A Case Report

Finkelman R., Munsat T., **Mandell H.**, Adelman L., Logigian E.

Neurology, 1993

Clinical Research:

Principal Investigator - Novartis: Passage: Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy. 2014

Curriculum Vitae
Howard Mandell, B.A., M.D., FRCPS

Principal Investigator - Novartis: Transition: A two-year observational study to evaluate the safety profile of fingolimod in patients with multiple sclerosis who switch from natalizumab to fingolimod. 2014

Principal Investigator - Sun Pharma Advances Research Company: A twenty one week study. The primary objectives are to compare the continued treatment with Baclofen ER capsules versus down-titration to placebo in subjects stabilized on Baclofen ER Capsules. 2014

Sub-Investigator - Allergan: AsPIRE: Adult Spasticity International Registry on BOTOX Treatment. 2014

Sub-Investigator - Biogen Idec MA: A multicenter, randomized, double-blind, placebo controlled study to assess the long-term efficacy and safety of prolonged release fampridine (BIIB041) 10 mg, administered twice daily in subjects with multiple sclerosis (ENHANCE). 2015


Principal Investigator - AZTherapies: A phase III safety and efficacy study of AZT-OP1 in subjects with evidence of early Alzheimer's disease. 2016 *High enrolling site

Sub-Investigator - Eli Lilly: A phase 3, randomized, double-blind, placebo-controlled study of LY2951742 in patients with Episodic migraine-the EVOLVE-1 study. 2016

Principal Investigator – Adamas Protocol ADS-AMT-MS301: A 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment. 2018

My signature verifies the information in these curriculum vitae is accurate and updated appropriately.


Signature


Date

